Recommended Imaging Approach for Infiltrative Liver Disorders
MRI abdomen without and with IV contrast is the preferred imaging modality for evaluating infiltrative liver disorders, with multiphase CT as an equivalent alternative when MRI is contraindicated or unavailable. 1
Primary Imaging Strategy
For suspected infiltrative liver disease, the imaging approach depends on the clinical context:
MRI Abdomen (Preferred Modality)
MRI provides superior tissue characterization for infiltrative processes through:
- T1-weighted sequences: Infiltrative lesions typically appear hypointense 2, 3
- T2-weighted sequences: Show mild to moderate hyperintensity 3, 4
- Diffusion-weighted imaging (DWI): Critical for detecting infiltrative HCC, which shows restricted diffusion with significantly lower ADC values compared to benign infiltrative processes like confluent fibrosis 4
- Hepatobiliary phase imaging: Improves outer margin clarity and helps distinguish infiltrative HCC from focal confluent fibrosis 4
- Dynamic contrast enhancement: Reveals heterogeneous arterial enhancement with variable washout patterns 2
MRI achieves 95% diagnostic accuracy for establishing definitive diagnoses in liver lesions, significantly higher than CT's 71-91% accuracy 1
Multiphase CT Abdomen (Alternative)
When MRI is unavailable or contraindicated:
- Triple-phase contrast-enhanced CT is recommended (arterial, portal venous, delayed phases) 1, 5
- Requires optimal technique: 2.5-5mm slice thickness, 4-5 mL/s injection rate 6
- Sensitivity of 72-91% for establishing diagnosis 1
Key Imaging Features to Identify
For Infiltrative HCC (Most Critical Differential)
Look for these distinguishing characteristics 4, 2:
- Lobulated margins (vs. straight/irregular margins in confluent fibrosis)
- Bulging or intact contours (vs. capsular retraction in fibrosis)
- Arterial phase enhancement with heterogeneous washout
- Satellite nodules (highly suggestive)
- Portal vein tumor thrombus
- Restricted diffusion on DWI with low ADC values
- Distinct outer margins on hepatobiliary phase compared to T2-weighted images
For Other Infiltrative Processes
- Confluent fibrosis: Straight or irregular margins, capsular retraction, higher ADC values, no arterial enhancement 4
- Diffuse fatty infiltration: Nonspherical shape, absence of mass effect, low density on contrast CT 7
Critical Pitfalls to Avoid
Single-phase imaging is inadequate - Always obtain multiphase studies for infiltrative disease evaluation 1, 5
Background cirrhosis obscures detection - Infiltrative lesions often blend into heterogeneous cirrhotic liver, requiring careful attention to subtle signal differences and contour abnormalities 2, 3, 8
Delayed diagnosis is common - Infiltrative HCC accounts for 8-20% of HCC cases but is frequently not discovered until advanced stages due to ill-defined borders 3, 8
Ultrasound has severe limitations - Shows markedly heterogeneous, ill-defined echotexture that cannot reliably distinguish infiltrative disease from cirrhosis 3
When to Consider Biopsy
Percutaneous image-guided biopsy should be performed when 1:
- Imaging features remain indeterminate after optimal MRI or CT
- Differentiation between infiltrative HCC and benign processes (like confluent fibrosis) cannot be established
- Histopathologic diagnosis would alter management (e.g., lymphoma consideration)
Use CT or ultrasound guidance depending on lesion visibility and accessibility 1
Special Considerations
In Chronic Liver Disease Patients
Follow LI-RADS criteria for lesion characterization 1, 5:
- Lesions ≥10mm require definitive diagnosis
- Apply multiphase CT or MRI per LI-RADS technical recommendations
- Arterial hyperenhancement with delayed washout has 89% sensitivity and 96% specificity for HCC 5
Contrast-Enhanced Ultrasound (CEUS)
May be appropriate as adjunct imaging 1:
- Correctly characterizes 76% of HCCs
- Distinguishes HCC from FNH with 82% accuracy
- Cannot adequately stage entire liver or assess for metastatic disease
Advanced MRI Techniques
Combination of DWI and hepatobiliary phase imaging allows correct classification of lesions as benign vs. malignant in 91% of cases 1